In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drug

Investigational New Drugs

Volumn 24, Issue 1, 2006, Pages 3-14

  Brandon, Esther F A ^a   Sparidans, Rolf W ^a   Guijt, Kees Jan ^a   Löwenthal, Sjoerd ^a   Meijerman, Irma ^a   Beijnen, Jos H ^a,b   Schellens, Jan H M ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Biotransformation; Conjugation; CYP reaction phenotype; Cytochrome P450 (CYP); ET 743

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; TRABECTEDIN; TRABECTIDIN;

ARTICLE; CATALYSIS; CONTROLLED STUDY; CYTOSOL; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; FEMALE; GLUCURONIDATION; HUMAN; LIVER MICROSOME METABOLISM; MALE; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SULFATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DIOXOLES; FEMALE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HUMANS; ISOQUINOLINES; MALE; MICROSOMES, LIVER; PHENOTYPE; SEX FACTORS; TETRAHYDROISOQUINOLINES;

EID: 31544458696     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-4538-9     Document Type: Article

References (43)

1. Jimeno JM: A clinical armamentarium of marine-derived anti-cancer compounds. Anticancer Drugs 13 (suppl 1):S15-S19, 2002
2. Rinehart KL, Gravalos LG, Faircloth G, Jimeno J: Ecteinascidin (ET-743): Preclinical antitumor development of a marine derived natural product (abstract). Proc Am Assoc Cancer Res 36:2322, 1995
3. Jimeno JM, Faircloth G, Cameron L, Meely K, Vega E, Gómez A, Fernández Sousa-Faro JM, Rinehart K: Progress in the acquisition of new marine-derived anticancer compounds: development of Ecteinascidin-743 (ET-743). Drugs of the Future 21:1155-1165, 1996
4. D'Incalci M, Erba E, Damia G, Galliera E, Carassa L, Marchini S, Mantovani R, Tognon G, Fruscio R, Jimeno J, Faircloth GT: Unique features of the mode of action of ET-743. The Oncologist 7:201-216, 2002
5. van Kesteren Ch, de Vooght MMM, López-Lázaro L, Mathôt RAA, Schellens JHM, Jimeno JM, Beijnen JH: Yondelis® (trabectedin, ET-743): The development of an anticancer agent of marine origen. Anticancer Drugs 14:487-502, 2003
6. Demetri GD, Manola J, Harmon D, Maki RG, Seiden MV, Supko JG, Ryan DP, Puchlaski TA, Goss G, Merriam P, Waxman A, Slater S, Potter A, Quigley MT, Lopez T, Sancho MA, Guzman C, Jimeno J, Garcia-Carbonero R: Ecteinascidin-743 (ET-743) induces durable responses and promising 1-year survival rates in soft tissue sarcomas (STS): Final results of phase II and pharmacokinetic studies in the U.S.A. (abstract). Proc Am Soc Clin Oncol 20:1406, 2001
7. Zelek L, Yovine A, Brain E, Turpin F, Taamma A, Riofrio M, Spielmann M, Jimeno J, Cvitkovic E: Preliminary results of phase II study of Ecteinascidin-743 with the 24 h continuous infusion Q3 weeks schedule in pretreated advanced/metastatic breast cancer patients (abstract). In: Proc 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands: 2000 p. 85a
8. Aune GJ, Furuta T, Pommier Y: Ecteinascidin-743: A novel anticancer drug with a unique mechanism of action. Anticancer Drugs 13:545-555, 2002
9. Reid JM, Kuffel MJ, Ruben SL, Morales JJ, Rinehart KL, Squillace DP, Ames MM: Rat and human liver cytochrome P-450 isoform metabolism of Ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin Cancer Res 8:2952-2962, 2002
10. Sparidans RW, Rosing H, Hillebrand MJX, López-Lázaro L, Jimeno JM, Manzanares I, van Kesteren Ch, Cvitkovic E, van Oosterom AT, Schellens JHM, Beijnen JH: Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man. Anticancer Drugs 12:653-666, 2001
11. Curry SH: Chapter 2. In: Drug disposition and pharmaconkinetics with a consideration of pharmacological and clinical relationships. Blackwell Scientific Publications, Oxford, 1974, pp. 42-48
12. Gibson GG, Skett P: Chapter 1. In Introduction to drug metabolism. Blackie Academic and Professional, London, 1994, pp. 1-34
13. www.gentest.com. Gentest, a Becton and Dickinson company. (accessed July 2003).
14. Crespi CL, Miller VP: The use of heterolously expressed drug metabolizing enzymes - State of the art and prospects for the future. Pharmacol Ther 84:121-131, 1999
15. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, Greenblatt DJ: Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493-1504, 2000
16. Stömer W, von Moltke LL, Greenblatt DJ: Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: A copmparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. J Pharmacol Exp Ther 295:793-801, 2000
17. van Kesteren Ch, Cvitkovic E, Taamma A, López-Lázaro L, Jimeno JM, Guzman C, Mathôt RAA, Schellens JHM, Misset J-L, Brian E, Hillebrand MJX, Rosing H, Beijnen JH: Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res 6:4725-4732, 2000
18. Puchalski TA, Ryan DP, Garcia-Carbonero R, Demetri GD, Butkiewicz L, Harmon D, Seiden MV, Maki RG, López-Lázaro L, Jimeno J, Guzman C, Supko JG: Pharmacokinetics of ecteinascidin 743 administred ad a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: Associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 50:309-319, 2002
19. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Ranee DJ, Wastall P: The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharamcol Exp Ther 283:46-58, 1997
20. www.gentest.com/human_p450_database. Gentest Cytochrome P450 database. (accessed January 2003)
21. Wienkers LC, Wynalda MA: Multiple cytochrome P450 enzymes responsible for the oxidative metabolism of the substituted (S)-3-phenylpiperidine, (S, S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, in human liver microsomes. Drug Metab Dispos 30:1372-1377, 2002
22. Ko JW, Desta Z, Soukhova NV, Tracy T, Flockhart DA: in vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: Potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol 49:343-351, 2000
23. Zhou S, Paxton JW, Tingle MD, Kestell P: Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metab Dispos 28:1449-1456, 2000
24. Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, Granneman GR: Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos 27:902-908, 1999.
25. Rodrigues AD: Integrated cytochrome P450 reaction phenotyping. Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-180, 1999
26. Lu AYH, Wang RW, Lin JH: Cytochrome P450 in vitro reaction phenotyping: A re-evaluattion of approaches used for P450 isofrom identification. Drug Metab Dispos 312:345-350, 2003
27. Brandon EFA, Raap CD, Meijerman I, Beijnen JH, Schellens JHM: An update on in vitro test methods in human hepatic drug biotransformation research: Pros and cons. Toxicol Appl Pharmacol 189:233-246, 2003
28. Lin JH: Sense and nonsense in the prediction of drug-drug interactions. Curr Drug Metab 1:305-331, 2000
29. Bachman KA, Ghosh R: The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions. Current Drug Metabolism 2:299-314, 2001
30. Lin JH, Lu AYH: Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390, 1998
31. Dahl ML: Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: Useful aid to prescribing? Clin Pharmacokinet 41:453-470, 2002
32. Tucker GT: The rationel selection of drug interaction studies: Implication of recent advantages in drug metabolism. Int J Clin Pharmacol Ther Toxicol 30:550-553, 1992
33. Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M: Metabolic drug intractions. Lippincott Williams and Wilkins, Philidelphia, 2000
34. Desai PB, Duan JZ, Zhu YW, Kouzi S: Human liver microsomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet 23:417-424, 1998
35. Laverdiere C, Kolb EA, Supko GJ, Gorlick R, Meyers PA, Maki RG, Wexler L, Demetri GD, Healey JH, Huvor AG, Goorin AM, Bagatell R, Ruiz-Casado A, Guzman C, Jimeno J, Harmon D. Phase II study of Ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 98:832-840, 2003
36. Donald S, Verschoyle RD, Greaves P, Colombo T, Zucchetti M, Falcioni C, Zaffaroni M, D'Incalci M, Manson MM, Jimeno J, Steward WP, Gescher AJ: Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma. Int. J. Cancer 111:961-967, 2004
37. Donald S, Verschoyle RD, Greaves P, Orr S, Jimeno J, Gescher AJ: Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro. Cancer Chemother. Pharmacol. 53:305-312, 2004
38. D'Incalci MD, Jimeno J: Preclinical and clinical results with the natural marine product ET-743. Exp. Opinion Invest Drugs 12:1843-1853, 2003
39. Tanaka E: Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 24:339-346, 1999
40. Wormhoudt LW, Commandeur JNM, Vermeulen NPE: Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: Relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol 29:59-124, 1999
41. Eiselt R, Domanski TL, Zibat A, Mueller R, Presecan-Siedel E, Hustert E, Zanger UM, Brockmoller J, Klenk HP, Meyer UA, Khan KK, He YA, Halpert JR, Wojnowski L: Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11:447-458, 2001
42. van Schaik RH, van der Heiden JP, van den Anker JN, Lindemans J: CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48:1668-1671, 2001
43. MacKenzie PI, Miners JO, McKinnon RA: Polymorphisms in UDP glucuronosyltransferase genes: Functional consequences and clincial relevance. Clin Chem Lab Med 38:889-892, 2000